Trial Profile

Efficacy and Safety of PUL-042 Inhalation Solution in Reducing Lower Respiratory Tract Complications in Patients with Hematologic Malignancies and Recipients of Hematopoietic Stem Cell Transplantation (HSCT) with Documented Viral Infections with PIV, HMPV or RSV

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 06 Aug 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ODN/Pam2 (Primary)
Indications Metapneumovirus infections; Parainfluenza virus infections; Respiratory syncytial virus infections
Focus Therapeutic Use
Sponsors Pulmotect

24 Apr 2026 Planned End Date changed from 1 May 2026 to 1 May 2027.
24 Apr 2026 Planned primary completion date changed from 1 Apr 2026 to 1 Apr 2027.
10 Jun 2025 Planned initiation date changed from 1 Apr 2025 to 1 Jun 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com